Comparison of relapse-free survival in gastric neuroendocrine carcinoma (WHO grade 3) and gastric carcinoma

BACKGROUND We compared relapse-free survival (RFS) in gastric neuroendocrine carcinoma (WHO grade 3) and gastric carcinoma (GC). This is one of very few studies that compare the prognosis of poorly differentiated neuroendocrine carcinoma (WHO grade 3, G3 NEC) with that of GC. METHODS Between 1996 and 2014, 63 patients were diagnosed with G3 NEC of the stomach and 56 with gastric neuroendocrine tumors (NETs) with GC at Asan Medical Center in Seoul, Korea. We also randomly selected 762 patients diagnosed with GC between 1999 and 2008. RESULTS Patients with G3 NEC tumors that invaded the muscularis propria or shallower had poorer RFS than those with GC of the same type, while G3 NEC that invaded the subserosa or deeper had similar RFS to GC of that type. Patients diagnosed with G3 NEC with N0 or N2 had poorer RFS than the corresponding patients with GC, while those who had G3 NEC with N1 or N3 had similar RFS to the corresponding patients with GC. G3 NEC patients had poorer RFS than well-differentiated, moderately differentiated and poorly differentiated GC patients, while G3 NEC patients had similar RFS to that of those with signet ring cell carcinoma (SRC). In addition, patients with G3 NEC of stages I or IIa had poorer RFS than those with corresponding GC, while G3 NEC stage IIb or greater had similar RFS to the corresponding GC. CONCLUSIONS Non-advanced G3 NEC showed poorer RFS than GC excluding SRC, while advanced G3 NEC has a similar RFS to that of GC without SRC. Therefore, we recommend that patients with non-advanced G3 NEC of the stomach be given a more aggressive treatment and surveillance than those with non-advanced GC excluding SRC.